- Home
- NRO vs TLSA Comparison
NRO vs TLSA Comparison
Compare NRO & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- TLSA
- Stock Information
- Founded
- NRO 2003
- TLSA 2013
- Country
- NRO United States
- TLSA United Kingdom
- Employees
- NRO N/A
- TLSA N/A
- Industry
- NRO Finance/Investors Services
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- NRO Finance
- TLSA Health Care
- Exchange
- NRO Nasdaq
- TLSA Nasdaq
- Market Cap
- NRO 156.7M
- TLSA 187.0M
- IPO Year
- NRO N/A
- TLSA 2000
- Fundamental
- Price
- NRO $3.28
- TLSA $1.64
- Analyst Decision
- NRO
- TLSA
- Analyst Count
- NRO 0
- TLSA 0
- Target Price
- NRO N/A
- TLSA N/A
- AVG Volume (30 Days)
- NRO 239.4K
- TLSA 369.4K
- Earning Date
- NRO 01-01-0001
- TLSA 05-06-2025
- Dividend Yield
- NRO 11.41%
- TLSA N/A
- EPS Growth
- NRO N/A
- TLSA N/A
- EPS
- NRO N/A
- TLSA N/A
- Revenue
- NRO N/A
- TLSA N/A
- Revenue This Year
- NRO N/A
- TLSA N/A
- Revenue Next Year
- NRO N/A
- TLSA N/A
- P/E Ratio
- NRO N/A
- TLSA N/A
- Revenue Growth
- NRO N/A
- TLSA N/A
- 52 Week Low
- NRO $2.51
- TLSA $0.63
- 52 Week High
- NRO $3.45
- TLSA $2.60
- Technical
- Relative Strength Index (RSI)
- NRO 54.65
- TLSA 42.25
- Support Level
- NRO $3.20
- TLSA $1.51
- Resistance Level
- NRO $3.34
- TLSA $1.90
- Average True Range (ATR)
- NRO 0.04
- TLSA 0.14
- MACD
- NRO 0.00
- TLSA -0.04
- Stochastic Oscillator
- NRO 50.00
- TLSA 29.03
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.